ERBB2 and breast carcinoma: In conclusion, triple combination targeting therapy (HER2 and CDK4/6 inhibitors combined with antihormonal therapy) remains promising in HR+/HER2+ breast cancer, given largely nonoverlapping resistance mechanisms to the agents in this combination.